Based near Geneva, Switzerland and founded in 1990, Stragen is primarily a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units.

Stragen is a leading pharmaceutical company targeting niche markets with more than 100 formulations developed and a portfolio of currently 40 products commercialized among several therapeutic areas namely cardiology and anti-infectives.

The company has a global presence in over 60 countries with a direct presence in key, established markets (predominantly France, Germany, Nordic European countries, USA and Canada) and a growing presence in numerous emerging markets (e.g., Algeria, Vietnam, etc.).

  • Investment date


  • Sector


  • Transaction type

    Buy-Out / Internationalization

  • Growth theme


  • Location